<DOC>
	<DOCNO>NCT01560104</DOCNO>
	<brief_summary>A Randomized , Double-Blind , Multicenter , Phase 2 Trial Comparing Veliparib Plus Carboplatin Paclitaxel Versus Placebo Plus Carboplatin Paclitaxel Previously Untreated Metastatic Advanced Non-Small-Cell Lung Cancer ( NSCLC ) .</brief_summary>
	<brief_title>A Clinical Study Conducted Multiple Centers Comparing Veliparib Combination With Carboplatin Paclitaxel Versus Placebo Combination With Carboplatin Paclitaxel Patients With Advanced Non-small Cell Lung Cancer</brief_title>
	<detailed_description>Subjects randomize 2:1 ratio one two treatment group . The safety treatment group assess evaluate study drug exposure , adverse event , serious adverse event , death , change laboratory determination vital sign parameter . Progression -Free Survival ( PFS ) use Response Evaluation Criteria Solid Tumors ( RECIST ) ( version 1.1 ) assess well Overall Survival ( OS ) Objective Response Rate ( ORR ) . Study visit conduct accord protocol schedule . Study visit include physical examination , laboratory blood sample collection , assessment vital sign , medical history urinalysis . 12-lead Electrocardiogram ( ECG ) perform protocol specify visit .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Veliparib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Life expectancy &gt; 12 week ( per Investigator 's clinical assessment ) . Subject must cytologically histologically confirm nonsmall cell lung cancer ( NSCLC ) . Subject must metastatic advanced nonsmall cell lung cancer ( NSCLC ) ( stage IIIB IV ) amenable surgical resection radiation curative intent time study Screening . Subject must least 1 unidimensional measurable nonsmall cell lung cancer ( NSCLC ) lesion Computed Tomography ( CT ) scan define Response Evaluation Criteria Solid Tumors ( RECIST ) ( version 1.1 ) . Subject must consent provide available archived formalin fix , paraffin embed ( FFPE ) tissue sample nonsmall cell lung cancer ( NSCLC ) lesion ( primary metastatic ) central review biomarker analysis . Subject must history brain metastasis evidence primary central nervous system ( CNS ) tumor demonstrate baseline magnetic resonance imaging ( MRI ) . Subject must Eastern Cooperative Oncology Group ( ECOG ) Performance Score 01 . Subjects fluid retention , include ascites pleural effusion , may allow discretion Investigator . Subject known hypersensitivity paclitaxel drug formulate polyethoxylated castor oil ( Cremophor ) . Subject know hypersensitivity platinum compound . Subjects peripheral neuropathy ≥ grade 2 . Subjects know epidermal growth factor receptor ( EGFR ) mutation exon 19 deletion L858R mutation exon 21 . ( Subjects wild type epidermal growth factor receptor ( EGFR ) , unknown status type epidermal growth factor receptor ( EGFR ) mutation consider eligible ) . Subject receive prior systemic anticancer therapy metastatic nonsmall cell lung cancer ( NSCLC ) . Subject receive adjuvant chemotherapy ≤ 12 month prior Cycle 1 Day 1 . Subject receive anticancer Chinese medicine anticancer herbal remedy within 14 day prior Cycle 1 Day 1 . Subject undergone External Beam Radiation Therapy ( EBRT ) ≤ 8 week prior Cycle 1 Day 1 . Clinically significant uncontrolled major medical condition ( ) . Subject previously treat poly ( ADPribose ) polymerase ( PARP ) inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Randomized</keyword>
	<keyword>metastatic</keyword>
	<keyword>ABT-888</keyword>
	<keyword>paclitaxel</keyword>
	<keyword>non-small cell lung cancer</keyword>
	<keyword>PARP</keyword>
	<keyword>veliparib</keyword>
	<keyword>progression free survival</keyword>
	<keyword>carboplatin</keyword>
</DOC>